TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25366688

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², once every 3 weeks)
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: No DTCs after treatment with docetaxel
Number of subjects: 1066

Group type: COMPARATOR
Intervention: No DTCs at BM1 and BM2
Number of subjects: 1066
Study: 25367064

Group type: EXPERIMENTAL
Intervention: Cough during therapeutic thoracentesis
Number of subjects: 0
Study: 25367412

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta (PEG-Epo)
Number of subjects: 785
Study: 25368957

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a for 48 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: PARC rule evaluated in a subset of 47 patients
Number of subjects: 95
Study: 25369108

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg, subcutaneously every 4 weeks for 6 months
Number of subjects: 43
Study: 25369558

Group type: EXPERIMENTAL
Intervention: Paired daily spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) in collaborative units.
Number of subjects: 5164

Group type: COMPARATOR
Intervention: Surveillance-only units (control group).
Number of subjects: 5164
Study: 25369725

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapies tailored to caregiver thinking patterns
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapies
Number of subjects: 90
Study: 25370510

Group type: EXPERIMENTAL
Intervention: Spectral-domain OCT (SD-OCT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Proprietary algorithm-derived measurements
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 126
Study: 25370513

Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT) with 3-D segmentation algorithm
Number of subjects: 126
Study: 25370536

Group type: EXPERIMENTAL
Intervention: Comprehensive in-hospital assessment including clinical characteristics, geriatric impairments, and health status measures.
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Follow-up for six months post-hospitalization.
Number of subjects: 3000
Study: 25370584

Group type: EXPERIMENTAL
Intervention: Actical accelerometers attached to both wrists, ankles, and hip for ≤7 days
Number of subjects: 100
Study: 25370626

Group type: EXPERIMENTAL
Intervention: Kilovoltage intrafraction monitoring (KIM)
Number of subjects: 0
Study: 25370961

Group type: EXPERIMENTAL
Intervention: NOAC treatment
Number of subjects: 20
Study: 25371383

Group type: COMPARATOR
Intervention: Sham tDCS over the left motor cortex and contralateral supraorbital cortex for 5 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active tDCS over the left motor cortex for 5 days after sham tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline anterior cingulate Glx levels
Number of subjects: 12
Study: 25371447

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Estrogens, progesterone, non-SHBG-bound testosterone, SHBG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 180
Study: 25371817

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 70
Study: 25371966

Group type: EXPERIMENTAL
Intervention: PER977
Number of subjects: 0

Group type: COMPARATOR
Intervention: edoxaban
Number of subjects: 0
Study: 25372029

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with SP and SP-PQ
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Malaria infection
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: S. mansoni infection
Number of subjects: 616
Study: 25372980

Group type: EXPERIMENTAL
Intervention: Phase-contrast MR imaging-derived duration of vortical blood flow (tvortex)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: tvortex-based diagnosis of PH
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: tvortex < 14.3%
Number of subjects: 145
Study: 25373117

Group type: EXPERIMENTAL
Intervention: MDD/SRI exposure
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: MDD/no SRI exposure
Number of subjects: 166

Group type: COMPARATOR
Intervention: Nonexposed infants
Number of subjects: 166
Study: 25373390

Group type: EXPERIMENTAL
Intervention: Daily text messages sent as an adjunct to group Cognitive Behavioral Therapy (CBT) for depression.
Number of subjects: 39
Study: 25374341

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg orally twice daily until disease progression or drug intolerance
Number of subjects: 12
Study: 25374386

Group type: EXPERIMENTAL
Intervention: Antithrombotic agents initiated in the prehospital phase
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Acetylic salicylic acid (ASA)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Any GP IIb/IIIa inhibitor
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Dual combination of ASA+(clopidogrel/prasugrel)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: ACE-I/ARB
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Combined use of five drug classes (ASA, P2Y12 antagonists, statin, beta blocker, ACE-I/ARB)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Bleeding complications
Number of subjects: 629
Study: 25374771

Group type: EXPERIMENTAL
Intervention: Homonymous visual field defects (HVFDs) patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Left-sided HVFD patients who passed the test
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy-sighted control subjects
Number of subjects: 20
Study: 25375257

Group type: EXPERIMENTAL
Intervention: MitraClip system
Number of subjects: 58
Study: 25375865

Group type: EXPERIMENTAL
Intervention: Double-lumen endotracheal tube (DLET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional endotracheal tube (ETT)
Number of subjects: 20
Study: 25375983

Group type: EXPERIMENTAL
Intervention: Mixed meals of 511, 743, and 1034 kcal
Number of subjects: 24
Study: 25376399

Group type: EXPERIMENTAL
Intervention: Weight loss surgery
Number of subjects: 242
Study: 25376618

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR (60 mg every 4 weeks)
Number of subjects: 29
Study: 25377157

Group type: EXPERIMENTAL
Intervention: 30 mg oral panobinostat (single dose)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 30 mg oral panobinostat (thrice weekly)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: BJB432 (metabolite of panobinostat)
Number of subjects: 37
Study: 25377177

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests for DR-TB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard mycobacterial growth indicator tube (MGIT) drug susceptibility tests
Number of subjects: 0
Study: 25377187

Group type: EXPERIMENTAL
Intervention: Prophylactic infusions of FXIII concentrate (human) 40 IU kg(-1) every 4 weeks for 12 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Prophylactic infusions of FXIII concentrate (human)
Number of subjects: 41
Study: 25377767

Group type: EXPERIMENTAL
Intervention: Biomechanical training program
Number of subjects: 25
Study: 25378645

Group type: EXPERIMENTAL
Intervention: ChAd3 (replicative defective simian adenoviral vector) followed by MVA (modified vaccinia Ankara) vector
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ChAd3 followed by MVA
Number of subjects: 0
Study: 25378660

Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: HSV-2-positive participants
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Ever-married adolescents
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Overall study participants
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Lower educational level and exam scores
Number of subjects: 837
Study: 25379192

Group type: EXPERIMENTAL
Intervention: Lower 25(OH)D levels
Number of subjects: 170

Group type: COMPARATOR
Intervention: Vitamin D status
Number of subjects: 170
Study: 25379854

Group type: EXPERIMENTAL
Intervention: ALPPS (Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: ALPPS (in patients younger than 60 years with CRLM)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 202
Study: 25379861

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 71
Study: 25380183

Group type: EXPERIMENTAL
Intervention: LGX818 (300 mg daily)
Number of subjects: 1
Study: 25380224

Group type: EXPERIMENTAL
Intervention: Transversal abdominal (TrA) muscle activation in LBP patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Transversal abdominal (TrA) muscle activation in pain-free participants
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lumbar multifidus (LM) muscle activation in LBP patients
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lumbar multifidus (LM) muscle activation in pain-free participants
Number of subjects: 73
Study: 25380582

Group type: COMPARATOR
Intervention: CAG repeat length 27-35
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: CAG repeat length 36-39
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Age 65 years or more
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Higher education (university degree or higher)
Number of subjects: 2167
Study: 25380636

Group type: EXPERIMENTAL
Intervention: Farletuzumab (administered by intravenous injection, dose escalation planned in 4 cohorts: 50, 100, 200, and 400 mg/m(2))
Number of subjects: 16
Study: 25380654

Group type: EXPERIMENTAL
Intervention: HER2 negative and intestinal type (Group A)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 positive and intestinal type (Group B)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 negative and diffuse type (Group C)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 positive and diffuse type (Group D)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 negative and mixed type (Group E)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 positive and mixed type (Group F)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: L-H status (combined Lauren classification and HER2 status)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 status in intestinal type patients
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 status in diffuse type patients
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: L-H status vs Lauren classification
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 negative and intestinal type
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: HER2 positive and diffuse type
Number of subjects: 838
Study: 25380704

Group type: EXPERIMENTAL
Intervention: Normal paced QRS axis
Number of subjects: 187

Group type: COMPARATOR
Intervention: Abnormal paced QRS axis
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Normal paced QRS axis among non-apical pacing
Number of subjects: 187
Study: 25380748

Group type: EXPERIMENTAL
Intervention: Personal vaporizers (PVs)
Number of subjects: 50
Study: 25380809

Group type: EXPERIMENTAL
Intervention: FAST symptoms
Number of subjects: 5023
Study: 25381092

Group type: EXPERIMENTAL
Intervention: Dual-isotope high-speed myocardial perfusion imaging (MPI)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 214
Study: 25381131

Group type: EXPERIMENTAL
Intervention: Vosaroxin (80-90 mg/m²) plus cytarabine (schedule A: 400 mg/m²/day, days 1-5; schedule B: 1 g/m²/day, days 1-5)
Number of subjects: 110
Study: 25382351

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial therapy (IT)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 937
Study: 25382415

Group type: EXPERIMENTAL
Intervention: Mother Program (MP)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Mother-Plus-Child Program (MPCP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Literature Control (LC)
Number of subjects: 202
Study: 25383091

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (H)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Monopolar Diathermy (MD)
Number of subjects: 42
Study: 25383099

Group type: EXPERIMENTAL
Intervention: Weight reduction program (diet control and exercise)
Number of subjects: 32
Study: 25384705

Group type: EXPERIMENTAL
Intervention: Carbon ion irradiation, median dose 36 Gy (RBE), range 36-51 Gy (RBE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Carbon ion irradiation
Number of subjects: 19
Study: 25384812

Group type: EXPERIMENTAL
Intervention: Health risk assessment
Number of subjects: 1707
Study: 25385094

Group type: EXPERIMENTAL
Intervention: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with methadone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Faldaprevir (240 mg QD for 8 days following a 480-mg loading dose) with buprenorphine-naloxone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Faldaprevir coadministration
Number of subjects: 34
Study: 25385099

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE) and Levonorgestrel (LNG) coadministered with 240 mg faldaprevir QD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ethinylestradiol (EE) and Levonorgestrel (LNG) alone
Number of subjects: 16
Study: 25385103

Group type: EXPERIMENTAL
Intervention: Miravirsen
Number of subjects: 0
Study: 25385345

Group type: EXPERIMENTAL
Intervention: ATP2B1 rs12817819 A allele
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Meta-analysis of INVEST and WISE
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: mRNA expression analysis
Number of subjects: 1741
Study: 25385409

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (plasma glucose 16 mmol/l)
Number of subjects: 8
Study: 25385439

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 13
Study: 25385737

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 36
Study: 25386767

Group type: EXPERIMENTAL
Intervention: ombitasvir-ABT-450/r and dasabuvir with ribavirin for 24 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ombitasvir-ABT-450/r and dasabuvir with ribavirin
Number of subjects: 34
Study: 25386899

Group type: EXPERIMENTAL
Intervention: Minimal Intervention Group (MIG) - goal to increase child's activity to 6000 pedometer steps/day above baseline, daily monitoring by parents
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intensive Intervention Group (IIG) - same steps/day and monitoring goals as MIG, plus text messages and articles with behavioral strategies
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison between MIG and IIG
Number of subjects: 27
Study: 25387065

Group type: EXPERIMENTAL
Intervention: TLC-GST
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: TLC-SCT
Number of subjects: 405

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 405
Study: 25387217

Group type: EXPERIMENTAL
Intervention: Albiglutide (subcutaneous administration, once-weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 0
Study: 25387261

Group type: EXPERIMENTAL
Intervention: CNP in children with achondroplasia
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CNP in adults with achondroplasia
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CNP in children with hypochondroplasia
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CNP in children with AMDM
Number of subjects: 96
Study: 25387866

Group type: EXPERIMENTAL
Intervention: Nilotinib prophylaxis after allogeneic stem cell transplantation (SCT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nilotinib prophylaxis after SCT
Number of subjects: 22
Study: 25387901

Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation
Number of subjects: 143
Study: 25387993

Group type: EXPERIMENTAL
Intervention: Septal reduction therapy (septal myectomy or alcohol septal ablation)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Endoscopic intervention and medical therapy for hypertrophic cardiomyopathy
Number of subjects: 77
Study: 25388099

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections, administered in cycles of two injections 24-72 hours apart, repeated after 6 weeks for ≤4 cycles.
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.58 mg, intralesional injections.
Number of subjects: 238
Study: 25388167

Group type: EXPERIMENTAL
Intervention: PF-04449913 640 mg once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PF-04449913 320 mg once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PF-04449913 80 to 320 mg once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PF-04449913
Number of subjects: 23
Study: 25389254

Group type: EXPERIMENTAL
Intervention: Booster vaccination for HCWs with anti-HBs <12 mIU/mL
Number of subjects: 59

Group type: COMPARATOR
Intervention: Initial vaccination
Number of subjects: 59
Study: 25389443

Group type: EXPERIMENTAL
Intervention: Zembrin 25 mg daily for 3 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25392649

Group type: EXPERIMENTAL
Intervention: Vaporization of ovarian endometriomas using plasma energy
Number of subjects: 22
Study: 25392936

Group type: EXPERIMENTAL
Intervention: Hyperfiltering adolescents with T1D (GFR ≥ 135 ml/min/1.73 m²)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Normofiltering adolescents with T1D (GFR < 135 ml/min/1.73 m²)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Healthy control subjects (HC)
Number of subjects: 142
Study: 25393047

Group type: EXPERIMENTAL
Intervention: Single-port sleeve gastrectomy (SPSG)
Number of subjects: 16
Study: 25393157

Group type: EXPERIMENTAL
Intervention: Procedure-related complications during islet transplantation
Number of subjects: 26
Study: 25393297

Group type: EXPERIMENTAL
Intervention: Early Onset (EO) MDD (18-29 years old)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Later Onset (LO) MDD (30-45 years old)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 61
Study: 25393520

Group type: EXPERIMENTAL
Intervention: Intermittent therapy (n = 118)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Daily therapy (n = 99)
Number of subjects: 217
Study: 25393536

Group type: EXPERIMENTAL
Intervention: 4 g/d omega-3 acid ethyl esters (P-OM3) for 8 weeks
Number of subjects: 15
Study: 25393601

Group type: EXPERIMENTAL
Intervention: Screening and care strategy
Number of subjects: 1745

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1745
Study: 25393640

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg/d for 2 weeks, followed by 1.2 mg/d) in addition to metformin (1500 mg/d)
Number of subjects: 20
Study: 25393648

Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg orally once daily for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 20
Study: 25394029

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) plus 2 NRTIs
Number of subjects: 87
Study: 25394040

Group type: EXPERIMENTAL
Intervention: CVC 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CVC 200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: EFV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CVC
Number of subjects: 30

Group type: COMPARATOR
Intervention: MVC
Number of subjects: 30
Study: 25394054

Group type: EXPERIMENTAL
Intervention: EFV-based HAART
Number of subjects: 357

Group type: COMPARATOR
Intervention: LPV/r-based HAART
Number of subjects: 357
Study: 25394093

Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy OD (LPVrMOD)
Number of subjects: 9
Study: 25394116

Group type: EXPERIMENTAL
Intervention: ART with TB co-infection
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: ART without TB co-infection
Number of subjects: 812

Group type: COMPARATOR
Intervention: Retention in care (both groups)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Mortality (both groups)
Number of subjects: 812

Group type: COMPARATOR
Intervention: CD4 cell count increase during treatment
Number of subjects: 812
Study: 25394136

Group type: EXPERIMENTAL
Intervention: Immunoglobulin at birth and complete vaccine schedule during the first six months of life
Number of subjects: 35

Group type: COMPARATOR
Intervention: Immunoglobulin and complete vaccine schedule
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lamivudine or tenofovir/emtricitabine during pregnancy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lamivudine during the last trimester
Number of subjects: 35
Study: 25394537

Group type: EXPERIMENTAL
Intervention: Azithromycin for at least 6 months
Number of subjects: 15
Study: 25395187

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 329
Study: 25395260

Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors without HBV prophylaxis (n=20)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors with lamivudine alone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors with lamivudine in combination with HBV immunoglobulin
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors
Number of subjects: 129

Group type: COMPARATOR
Intervention: Kidney transplantation from HBsAg(-) donors
Number of subjects: 129
Study: 25395425

Group type: EXPERIMENTAL
Intervention: Ibritumomab tiuxetan consolidation after 3 cycles of CHOP plus IFRT
Number of subjects: 46

Group type: COMPARATOR
Intervention: CHOP chemotherapy plus IFRT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 46